Sutra TMVR


Mitral regurgitation (MR) is the most prevalent valvular heart disease in the U.S., affecting approximately 1.7% of the population. MR prevalence increases with age, rising from 0.5% among 18-44 year olds to 9.3% among those aged 75 years and older [1,2]. There are 4.1 million patients in the US with moderate to severe MR requiring treatment. However, only approximately 30,000 patients in the U.S. undergo surgery for MR each year [3]. The vast majority of patients are not treated today because of the concerns about procedural complexity and patient safety during open-heart surgery. Transcatheter mitral valve repair (TMVRep) or replacement (TMVR) offer less invasive treatment options for MR patients. However, after more than a decade of development, the field of transcatheter mitral valve therapy is still in its infancy. Many of the current TMVRep and TMVR devices have dismal clinical results.


Sutra TMVR is a percutaneous, transcatheter bioprosthetic MV replacement system that bridges the best aspects of TMVR and TMVRep approaches.

Click here for more Sutra Updates

[1] Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146-e603.
[2] Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.
[3] Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.

Note: Sutra TMVR is not approved for investigational use or sale in the United States.